Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CDKN2A negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

CDKN2A overexpression (4)

CDKN2A expression (0)

CDKN2A overexpression (4)

CDKN2A expression (0)

›

CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
CDKN2A negative	Mesothelioma	CDKN2A negative	Mesothelioma	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3	abemaciclib Sensitive: C3 – Early Trials abemaciclib Sensitive : C3
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	nivolumab + cetuximab Sensitive: C3 – Early Trials nivolumab + cetuximab Sensitive : C3	nivolumab + cetuximab Sensitive: C3 – Early Trials nivolumab + cetuximab Sensitive : C3
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3